Physician profile
Joseph G Mcquade
NPI 1710959325
$4,418.47
in general payments reported to CMS, 2019-2025
28 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $386 · 2022: $268 · 2023: $577 · 2024: $1,155 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $744.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $512.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $391.25 | 2019-2025 | |
| Lilly USA, LLC | $379.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $292.46 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $270.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.02 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $201.83 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $192.68 | 2023-2024 | |
| Abbvie INC. | $158.75 | 2019-2025 | |
| Dexcom, INC. | $140.10 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $94.13 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $93.33 | 2019-2020 | |
| Astellas Pharma US INC | $93.16 | 2023-2025 | Myrbetriq, Veozah |
| Phathom Pharmaceuticals, INC. | $80.33 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $77.80 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $73.36 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $60.72 | 2019-2024 | Xarelto |
| Sanofi Pasteur INC. | $55.61 | 2022-2023 | |
| Allergan, INC. | $54.54 | 2019-2020 | |
| Hologic Sales and Service, LLC | $49.46 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Sumitomo Pharma America, INC. | $47.80 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $37.62 | 2019-2020 | |
| Vivus LLC | $17.02 | 2023 | Qsymia |
| Ibsa Pharma INC. | $16.87 | 2019 | |
| Medtronic, INC. | $15.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.04 | 2020 | |
| Upsher-Smith Laboratories LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mcquade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.